Combination therapy before and after stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three treatments (fruquintinib, sintilimab, and SOX chemotherapy) given before and after surgery for stomach cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that has spread to deeper layers or nearby lymph nodes but not to other organs.
- You are healthy enough for daily activities (ECOG score 0 or 1).
- You have not had any treatment for this cancer before.
- You do not have uncontrolled high blood pressure or a history of blood clots or bleeding in the stomach.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial is testing a combination of three drugs—sintilimab, fruquintinib, and standard chemotherapy—as a first treatment for advanced stomach cancer that cannot be surgically removed. The goal is to see if this combination can shrink the cancer enough to allow surgery, potentially improving outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests three drugs together—tafolecimab, sintilimab, and chemotherapy (SOX)—to treat advanced stomach cancer that cannot be removed by surgery. The drugs work in different ways to help your immune system fight cancer cells.
This trial tests a combination of fruquintinib (a pill that blocks blood vessel growth), sintilimab (an immunotherapy), and targeted radiation for people with stomach or GEJ cancer that has only a few new spots after at least one prior treatment. The goal is to see if this triple approach helps control the cancer better than standard options.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.